

JW/1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Sander Jan Hendrik VAN DEVENTER, *et al.*

Serial. No. 10/506,881

Filed: September 7, 2004

For: IL-10 GENE TRANSFER TO PERIPHERAL  
BLOOD MONONUCLEAR CELLS

Art Unit: 1646

Examiner: TBA

Confirmation No.: 6763

Atty. Docket No. 28902.0011

Customer No. 30827

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENT FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

In response to the Notification to Comply with Requirements for Patent Applications  
Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed February 28, 2006,  
Applicants respectfully submit:

- Statement and Sequence Listing in paper and computer readable format
- Copy of Notification to Comply with Requirements for Patent Applications Containing  
Nucleotide and/or Amino Acid Sequence Disclosures

In light of the foregoing, this application is deemed to be in proper condition for  
examination and such favorable action is earnestly solicited.

If any additional fees are required to complete the filing of this response, this is to serve as authorization for the extra fees to be charged to Deposit Account No. 50-0911. Please also credit any overpayment to Deposit Account No. 50-0911.

Respectfully submitted,

Dated: April 14, 2006

By

  
Shmuel Livnat

Registration No.: 33,949

MCKENNA LONG & ALDRIDGE LLP


1900 K Street, N.W.

Washington, DC 20006

Telephone: (202) 496 7500

Telefax: (202) 496 7756

Attorneys for Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/506,881	Sander Jan Hendrik Van Deventer	28902.nob11

30827  
 MCKENNA LONG & ALDRIDGE LLP  
 1900 K STREET, NW  
 WASHINGTON, DC 20006

INTERNATIONAL APPLICATION NO.	
PCT/NL03/00170	
I.A. FILING DATE	PRIORITY DATE
03/07/2003	03/07/2002

CONFIRMATION NO. 6763

371 FORMALITIES LETTER



\*OC000000018155604\*

Date Mailed: 02/28/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/506,881	PCT/NL03/00170	28902.nob11

FORM PCT/DO/EO/922 (371 Formalities Notice)